Every material Form 8-K Foghorn Therapeutics Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Foghorn Therapeutics reported third-quarter 2026 net income of $58.2 million, compared with a net loss of $15.8 million a year earlier, on collaboration revenue of $83.5 million, up from $8.2 million. Most of the revenue increase came from a $74.1 million cumulative catch-up adjustment tied to updated estimated future costs for ending the FHD-909 and SMARCA2 selective degrader programs, so the result is largely a one-time accounting effect.
Diluted earnings per share were $0.80, compared with a loss of $0.25 per share in the prior-year quarter.
Research and development expenses fell to $18.8 million from $20.0 million, and general and administrative expenses fell to $5.8 million from $6.7 million.
A new $2.3 million restructuring cost line appeared in the quarter.
Cash, cash equivalents and marketable securities were $156.2 million at September 30, 2026, with cash runway into the second half of 2029.
Foghorn Therapeutics and Eli Lilly decided not to advance the FHD-909 Phase 1 trial into its expansion phase, and the collaboration will not pursue further activities. Foghorn approved a strategic reprioritization and a workforce reduction of about 40%, leaving about 65 full-time employees, with aggregate charges of about $2.3 million mostly for severance and benefits. The company says the changes are expected to extend its cash runway into the second half of 2029.
Decision not to advance FHD-909 into expansion phase made September 25, 2026, after review of Phase 1 clinical data
Board approved reprioritization and workforce reduction on September 30, 2026; about 40% of current workforce affected, leaving about 65 full-time employees
Aggregate charges of approximately $2.3 million, expected to be incurred mainly in the fourth quarter of 2026
Press release says changes are expected to extend cash runway into the second half of 2029
Foghorn Therapeutics reported second quarter 2026 results, with collaboration revenue rising to $16.1 million and net loss narrowing to $7.2 million from $17.9 million a year earlier. Revenue was boosted by a $14.2 million cumulative catch-up adjustment tied to the December 2026 expiration of the Lilly research term, and the company said the CBPd-171 timeline has been delayed by an operational issue at a third-party contract research organization.
Collaboration revenue was $16.1 million for the quarter ended June 30, 2026, up from $7.6 million, including a $14.2 million cumulative catch-up adjustment.
Research and development expenses fell to $18.5 million from $21.8 million, and general and administrative expenses fell to $6.4 million from $6.9 million.
Cash, cash equivalents and marketable securities were $167.6 million as of June 30, 2026, with cash runway into the first half of 2028.
The CBPd-171 timeline was delayed; the company will provide updated guidance once available.
Foghorn Therapeutics reported first-quarter 2026 results, with collaboration revenue down to $3.3 million from $6.0 million a year earlier and a net loss of $19.9 million, up from $18.8 million. Net loss per share was $0.29, versus $0.30 a year earlier, on a larger share count of 69,540,075 weighted average shares. The company said it had $183.6 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the first half of 2028.
Collaboration revenue was $3.3 million for the quarter ended March 31, 2026, down $2.7 million from $6.0 million, due to the timing of work under the Lilly Collaboration Agreement.
Net loss was $19.9 million, compared with $18.8 million a year earlier; research and development expenses fell to $18.3 million from $21.6 million.
Net loss per share was $0.29, compared with $0.30 a year earlier.
Cash, cash equivalents and marketable securities were $183.6 million as of March 31, 2026, with cash runway into the first half of 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Foghorn Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →